I5154
IgG1, Kappa from human myeloma plasma
purified immunoglobulin, >95% (SDS-PAGE)
Synonym(s):
Human IgG1-κ
Product Name
IgG1, Kappa from human myeloma plasma, purified immunoglobulin, >95% (SDS-PAGE)
biological source
human
conjugate
unconjugated
antibody form
purified immunoglobulin
assay
>95% (SDS-PAGE)
application(s)
research pathology
shipped in
dry ice
storage temp.
−20°C
Quality Level
Looking for similar products? Visit Product Comparison Guide
Analysis Note
Identity is determined by immunoelectrophoresis and indirect ELISA.
Application
The purified IgG1, κ may be used as an immunoglobulin calibrator, reference antigen, blocking agent or coating protein in a variety of immunoassays including ELISA, dot-blot immunobinding, Western immunoblotting, immunodiffusion, immunoelectrophoresis, hemagglutination, and cell-binding assays. Human myeloma IgG1, κ was injected into mice (500 μg) to assess the T cell and B cell responses and also used for flow cytometry in CHO cells.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
IgG antibody subtype is the most abundant serum immunoglobulins of the immune system. It is secreted by B cells and is found in blood and extracellular fluids and provides protection from infections caused by bacteria, fungi and viruses. Maternal IgG is transferred to fetus through the placenta that is vital for immune defence of the neonate against infections. IgG1 is the most abundant of the IgG subclass
Human myeloma IgG1, κ is purified from human plasma by fractionation, ion-exchange, and affinity chromatography procedures.
Human myeloma IgG1, κ is purified from human plasma by fractionation, ion-exchange, and affinity chromatography procedures.
Physical form
Solution in 0.02 M Tris buffered saline, pH 8.0.
Storage Class
10 - Combustible liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
常规特殊物品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Johnny W Peterson et al.
Infection and immunity, 74(2), 1016-1024 (2006-01-24)
Prevention of inhalation anthrax requires early and extended antibiotic therapy, and therefore, alternative treatment strategies are needed. We investigated whether a human monoclonal antibody (AVP-21D9) to protective antigen (PA) would protect mice, guinea pigs, and rabbits against anthrax. Control animals
Bas Cornelis Jansen et al.
PloS one, 13(7), e0200280-e0200280 (2018-07-07)
High-performance liquid chromatography (HPLC) is widely used for absolute quantitation. The advent of new columns and HPLC technology has enabled higher sample throughput, and hence, larger scale studies that perform quantitation on different sample types (e.g. healthy controls vs. patients
Michael Y Choi et al.
Cell stem cell, 22(6), 951-959 (2018-06-03)
Cirmtuzumab is a humanized monoclonal antibody (mAb) that targets ROR1, an oncoembryonic orphan receptor for Wnt5a found on cancer stem cells (CSCs). Aberrant expression of ROR1 is seen in many malignancies and has been linked to Rho-GTPase activation and cancer
Yann Gallais et al.
Immunology and cell biology, 95(3), 306-315 (2016-10-08)
Patients treated with therapeutic biological products (BP) frequently develop anti-drug antibodies (ADA) with potential neutralizing capacities leading to loss of clinical response or serious side effects. BP aggregates have been suggested to promote immunogenicity, thus enhancing ADA production. Dendritic cells
Juan Manuel García-Martínez et al.
Molecular cancer therapeutics, 20(1), 96-108 (2020-10-11)
Activation of TRAILR2 has emerged as an important therapeutic concept in cancer treatment. TRAILR2 agonistic molecules have only had limited clinical success, to date, due either to lack of efficacy or hepatotoxicity. BI 905711 is a novel tetravalent bispecific antibody
Related Content
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service